Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

doi:10.4251/wjgo.v16.i4.1281

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1669)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-6) series.

Item

Count

PDF

113

HTML

1071

Tables (1-6)

147

Sum=1331

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

229

Sum=274

Apr 15, 2024 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1281-1295
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1281

Table 1 Demographic data before surgery

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	χ²	P value
Gender			0.080	0.777
Male	21 (75%)	44 (72.58%)
Female	7 (25%)	17 (27.42%)
Age			0.107	0.743
< 60	10 (35.71%)	24 (38.71%)
≥ 60	18 (64.29%)	37 (61.29%)
BMI			1.684	0.431
< 18.5	4 (14.29%)	10 (16.39%)
18.5-23	19 (67.86%)	33 (54.10%)
≥ 23	5 (17.86%)	18 (29.51%)
Tumor location			2.101	0.350
Upper	6 (21.43%)	15 (24.59%)
Middle	12 (42.86%)	33 (54.10%)
Lower	10 (35.71%)	13 (21.31%)
cT stage			0.297	0.586
T1/T2	5 (8.06%)	14 (22.58%)
T3/T4	23 (37.10%)	47 (77.42%)
cN stage			1.099	0.295
N0	3 (10.71%)	12 (19.67%)
N1-N3	25 (89.29%)	49 (80.32%)
cM stage			0.670	0.413
0	23 (82.14%)	54 (88.91%)
1	5 (17.86%)	7 (11.29%)
cTNM stage			0.351	0.554
I and II	7 (11.29%)	19 (32.26%)
III and IV	21 (33.87%)	42 (67.74%)
Neoadjuvant cycle			0.053	0.817
≤ 3	20 (71.43%)	45 (72.58%)
> 3	8 (28.57%)	16 (27.42%)
Operation mode			0.149	0.700
Open surgery	25 (89.29%)	56 (91.94%)
Laparoscopy	3 (10.71%)	5 (8.06%)
Adverse chemotherapy reaction			0.610	0.435
Yes	6 (21.43%)	9 (14.52%)
No	22 (78.57%)	52 (85.24%)
Differentiation			1.140	0.286
Well and middle	5 (17.86%)	6 (9.84%)
Poor and under-differentiated	23 (82.14%)	55 (90.16%)
Borrmann type			0.279	0.597
Big III	15 (53.58%)	29 (47.54%)
IV	13 (46.43%)	32 (52.46%)
AFP¹ (ng/mL)			0.566	0.452
≤ 8.1	20 (71.43%)	43 (70.49%)
> 8.1	2 (7.14%)	8 (13.11%)
Unknown	6 (21.43%)	10 (16.39%)
CEA¹ (ng/mL)			0.123	0.726
≤ 5	16 (57.14%)	35 (57.38%)
> 5	6 (21.43%)	16 (26.23%)
Unknown	6 (21.43%)	10 (16.39%)
CA199¹ (U/mL)			0.123	0.726
≤ 37	16 (57.14%)	35 (57.38%)
> 37	6 (21.43%)	16 (26.23%)
Unknown	6 (21.43%)	10 (16.39%)
CA724¹ (U/mL)			0.432	0.511
≤ 6.9	12 (42.86%)	32 (52.46%)
> 6.9	10 (35.71%)	19 (31.15%)
Unknown	6 (21.43%)	10 (16.39%)
CA125¹ (U/mL)			4.477	0.034^a
≤ 35	13 (46.43%)	42 (68.85%)
> 35	9 (32.14%)	9 (14.75%)
Unknown	6 (21.43%)	10 (16.39%)
CA50¹ (U/mL)			0.003	0.956
≤ 25	18 (64.29%)	42 (68.85%)
> 25	4 (14.29%)	9 (14.75%)
Unknown	6 (21.43%)	10 (16.39%)
Leukemia¹			0.228	0.892
≤ 3.5	1 (3.57%)	3 (4.92%)
3.5-9.5	19 (67.86%)	43 (70.49%)
> 9.5	3 (10.71%)	5 (8.20%)
Unknown	5 (8.20%)	10 (16.39%)
HGB¹			0.473	0.492
≤ 130	18 (64.29%)	36 (59.02%)
130-175	5 (8.20%)	15 (24.59%)
> 175	0	0
Unknown	5 (8.20%)	10 (16.39%)
Platelets¹			0.806	0.668
≤ 125	2 (7.14%)	2 (3.28%)
125-350	16 (57.14%)	39 (63.93%)
> 350	5 (8.20%)	10 (16.39%)
Unknown	5 (8.20%)	10 (16.39%)
Neutrophils¹			0.667	0.716
≤ 1.8	1 (3.57%)	4 (6.56%)
1.8-6.3	18 (64.29%)	41 (67.21%)
> 6.3	4 (14.29%)	6 (9.84%)
Unknown	5 (8.20%)	10 (16.39%)
Lymphocytes¹			0.084	0.772
≤ 1.1	8 (28.57%)	16 (26.23%)
1.1-3.2	15 (53.57%)	35 (57.38%)
> 3.2	0	0
Unknown	5 (8.20%)	10 (16.39%)
AFP² (ng/mL)			0.078	0.781
≤ 8.1	20 (71.43%)	46 (75.41%)
> 8.1	4 (14.29%)	11 (18.03%)
Unknown	4 (14.29%)	4 (6.56%)
CEA² (ng/mL)			2.806	0.094
≤ 5	22 (78.57%)	43 (70.49%)
> 5	2 (7.14%)	14 (22.95%)
Unknown	4 (14.29%)	4 (6.56%)
CA199² (U/mL)			0.507	0.476
≤ 37	22 (78.57%)	49 (80.33%)
> 37	2 (7.14%)	8 (13.11%)
Unknown	4 (14.29%)	4 (6.56%)
CA724² (U/mL)			2.034	0.154
≤ 6.9	18 (64.29%)	32 (52.46%)
> 6.9	6 (21.43%)	23 (37.70%)
Unknown	4 (14.29%)	6 (9.84%)
CA125² (U/mL)			0.043	0.835
≤ 35	23 (82.14%)	54 (88.52%)
> 35	1 (3.57%)	3 (4.92%)
Unknown	4 (14.29%)	4 (6.56%)
CA50² (U/mL)			0.583	0.445
≤ 25	22 (78.57%)	47 (77.05%)
> 25	2 (7.14%)	8 (13.11%)
Unknown	4 (14.29%)	6 (9.84%)
Leukemia²			1.181	0.554
≤ 3.5	7 (25%)	12 (19.67%)
3.5-9.5	16 (57.14%)	43 (70.49%)
> 9.5	3 (10.71%)	4 (6.56%)
Unknown	2 (7.14%)	2 (3.28%)
HGB²			0.662	0.416
≤ 130	23 (82.14%)	48 (78.69%)
130-175	3 (10.71%)	11 (18.03%)
Unknown	2 (7.14%)	2 (3.28%)
Platelets²			0.614	0.433
≤ 125	7 (25%)	21 (34.43%)
> 125	19 (67.86%)	38 (62.30%)
Unknown	2 (7.14%)	2 (3.23%)
Neutrophils²			0.730	0.673
≤ 1.8	6 (21.43%)	13 (21.31%)
1.8-6.3	17 (60.71%)	42 (68.85%)
> 6.3	3 (10.71%)	4 (6.56%)
Unknown	2 (7.14%)	2 (3.23%)

¹Tumor markers at first diagnosis.

²Preoperative tumor markers.

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; BMI: Body mass index; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen199; HGB: Hemoglobin; cTNM: Clinical tumor node metastasis.

Citation: Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol 2024; 16(4): 1281-1295
URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1281.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1281